Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study
Journal of Veterinary Internal Medicine2017Vol. 32(1), pp. 72–85
Citations Over TimeTop 10% of 2017 papers
Adrian Boswood, Sonya G. Gordon, Jens Häggström, Gerhard Wess, Rebecca L. Stepien, Mark A. Oyama, Bruce W. Keene, John D. Bonagura, Kristin A. MacDonald, Mark Patteson, Sarah Smith, Philip R. Fox, Karen Sanderson, Richard Woolley, Viktor Szatmári, Pierre Menaut, Whitney M. Church, M. Lynne O’Sullivan, J.‐P. Jaudon, Jan‐Gerd Kresken, John E. Rush, Kirstie A. Barrett, Steven L. Rosenthal, Ashley B. Saunders, Ingrid Ljungvall, Michael Deinert, Éric Bomassi, Amara H. Estrada, María Josefa Fernández del Palacio, N. Sydney Möise, Jonathan A. Abbott, Yoko Fujii, Alan W. Spier, Michael W. Luethy, Roberto A. Santilli, Masami Uechi, Anna Tidholm, Christoph Schummer, Philip Watson
Abstract
Pimobendan treatment reduces heart size. Reduced heart size is associated with improved outcome. At the onset of CHF, dogs treated with pimobendan were indistinguishable from those receiving placebo.
Related Papers
- Коммуникaтивно- прaгмaтический aнaлиз дипломaтических бумaг (нa основе вербaльных нот)(2018)
- FEATURES AND DIFFERENCES OF ADEQUATE AND EQUIVALENT TRANSLATION(2018)
- चितलवाना पंचायत समिति में मानव गरीबी सूचकांक - 2016 ( à¤à¤• गà¥à¤°à¤¾à¤® सà¥à¤¤à¤°à¥€à¤¯ à¤à¥Œà¤—ोलिक अधà¥à¤¯à¤¯à¤¨ )(2017)
- → ФОРМИРОВAНИЕ ГОТОВНОСТИ БУДУЩИХ ПЕДAГОГОВ К ОРГAНИЗAЦИИ РAБОТЫ ПО РAЗВИТИЮ ВAЛЕОЛОГИЧЕСКОЙ КУЛЬТУРЫ ШКОЛЬНИКОВ(2023)